Editorial: Tenofovir Alafenamide Versus Entecavir for Hepatitis B Surface Antigen Decline–A Step Toward Functional Cure or a Marginal Margin?
Alimentary Pharmacology & Therapeutics · 2026-08 · 64 (3) · 404-405
DOI: 10.1111/apt.70734 ↗At a glance
Editorial in Alimentary Pharmacology & Therapeutics, published online on 2026-05-15. Written by Yao-Chun Hsu and 1 co-authors. Institution: Department of Medical Research, E-Da Hospital, Kaohsiung, Taiwan. Cited 1 times so far (Crossref); 10 references. The full text is freely available in PubMed Central.
Abstract (original language)
Intet abstract tilgængeligt.
Authors and institutions
- Department of Medical Research, E-Da Hospital, Kaohsiung, Taiwan.
- School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan.
- Division of Hepatobiliary, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
- School of Medicine and Hepatitis Research Center, College of Medicine and Center for Liquid Biopsy and Cohort Research, Kaohsiung Medical University, Kaohsiung, Taiwan.
ORCID profiles: Yao-Chun Hsu, Ming-Lung Yu
Cite
APA
Hsu, Y. C., & Yu, M. L. (2026). Editorial: Tenofovir Alafenamide Versus Entecavir for Hepatitis B Surface Antigen Decline–A Step Toward Functional Cure or a Marginal Margin?. Alimentary Pharmacology & Therapeutics, 64(3), 404-405. https://doi.org/10.1111/apt.70734
Vancouver
Hsu YC, Yu ML. Editorial: Tenofovir Alafenamide Versus Entecavir for Hepatitis B Surface Antigen Decline–A Step Toward Functional Cure or a Marginal Margin?. Alimentary Pharmacology & Therapeutics. 2026;64(3):404-405. doi:10.1111/apt.70734
BibTeX
@article{Hsu2026,
author = {Hsu, Yao-Chun and Yu, Ming-Lung},
title = {Editorial: Tenofovir Alafenamide Versus Entecavir for Hepatitis B Surface Antigen Decline–A Step Toward Functional Cure or a Marginal Margin?},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
volume = {64},
number = {3},
pages = {404--405},
doi = {10.1111/apt.70734}
}
EUVIMED